Ftse Mib
34.897,57
0,48%
DAX
20.415,82
0,01%
S&P 500
6.059,92
-0,40%
NASDAQ
19.945,62
-0,45%
Bitcoin
100.962,51
-0,22%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ IO Biotech Inc (IOBT) IO Biotech Inc (IOBT) Notizie

IOBT

IO Biotech (IOBT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IOBT
DataOraFonteTitoloSimboloCompagnia
12/11/202422:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOBTIO Biotech Inc
12/11/202413:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
12/11/202413:05GlobeNewswire Inc.IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
11/11/202422:05GlobeNewswire Inc.IO Biotech Announces Participation in Upcoming Investor ConferencesNASDAQ:IOBTIO Biotech Inc
07/11/202416:00GlobeNewswire Inc.IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 StudyNASDAQ:IOBTIO Biotech Inc
04/10/202415:00GlobeNewswire Inc.IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:IOBTIO Biotech Inc
14/09/202408:30GlobeNewswire Inc.IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck CancerNASDAQ:IOBTIO Biotech Inc
30/08/202422:05GlobeNewswire Inc.IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced MelanomaNASDAQ:IOBTIO Biotech Inc
13/08/202413:05GlobeNewswire Inc.IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
25/07/202422:05GlobeNewswire Inc.IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024NASDAQ:IOBTIO Biotech Inc
07/06/202422:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOBTIO Biotech Inc
23/05/202414:30GlobeNewswire Inc.IO Biotech to Present at Jefferies Global Healthcare ConferenceNASDAQ:IOBTIO Biotech Inc
14/05/202413:55GlobeNewswire Inc.IO Biotech Reports First Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
24/04/202422:30GlobeNewswire Inc.IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:IOBTIO Biotech Inc
15/04/202414:30GlobeNewswire Inc.IO Biotech Expands Senior Leadership Team to Progress Commercialization ReadinessNASDAQ:IOBTIO Biotech Inc
09/04/202418:00GlobeNewswire Inc.IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103NASDAQ:IOBTIO Biotech Inc
05/04/202414:30GlobeNewswire Inc.IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business OfficerNASDAQ:IOBTIO Biotech Inc
11/03/202421:56Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IOBTIO Biotech Inc
06/03/202422:11GlobeNewswire Inc.IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:IOBTIO Biotech Inc
05/03/202423:17Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IOBTIO Biotech Inc
05/03/202422:40GlobeNewswire Inc.IO Biotech Announces 2023 Fourth-Quarter and Year-End ResultsNASDAQ:IOBTIO Biotech Inc
26/02/202422:05GlobeNewswire Inc.IO Biotech to Present at 44th Annual Cowen Health Care ConferenceNASDAQ:IOBTIO Biotech Inc
21/12/202314:30GlobeNewswire Inc.IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket TrialNASDAQ:IOBTIO Biotech Inc
13/11/202314:12GlobeNewswire Inc.IO Biotech Announces 2023 Third Quarter ResultsNASDAQ:IOBTIO Biotech Inc
13/11/202314:00GlobeNewswire Inc.IO Biotech Appoints Helen Collins, MD, to its Board of DirectorsNASDAQ:IOBTIO Biotech Inc
10/11/202314:00GlobeNewswire Inc.IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced MelanomaNASDAQ:IOBTIO Biotech Inc
01/11/202313:30GlobeNewswire Inc.IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:IOBTIO Biotech Inc
23/10/202307:00GlobeNewswire Inc.Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European SocieNASDAQ:IOBTIO Biotech Inc
03/10/202322:30GlobeNewswire Inc.IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:IOBTIO Biotech Inc
12/09/202322:06Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:IOBTIO Biotech Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IOBT

La tua Cronologia

LSE
RTW
Rtw Biotech Opportunities
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network